OmniComm Systems Inc. announced today that Anju Software Inc. has completed the acquisition of OmniComm Systems, Inc. (OTCQX: OMCM), a leading strategic software solutions provider to the life sciences industry. Under the terms of the agreement, OmniComm is now a wholly owned subsidiary of Anju, a provider of data software and services to life science companies, contract research organizations and medical device manufacturers. Anju is a privately owned, Abry Partners portfolio company.
The merger of OmniComm and Anju positions the combined organization as a leader in the eClinical solutions market, with particular expertise in electronic data capture and eSource. Anju is able to immediately add CTMS, eTMF, data migration and integration tools and dynamic reporting, integrated with the existing solutions, to the OmniComm suite of eClinical solutions. As part of the merger, OmniComm’s solutions, including its flagship TrialMaster® and TrialOne® products, will continue to be developed and supported with enhanced features to provide a complete eClinical suite.
“I have been working on this transaction with Anju for the past two years, and this merger represents the next chapter in OmniComm’s evolution from a small independent eClinical company into a more comprehensive global provider of software and services for the larger life sciences and medical device community,” said Randall Smith, Founder and Vice Chairman of OmniComm.
“By joining forces with Anju, we will accelerate our shared goal of becoming the best-in-class platform for eClinical solutions and clinical trials management,” added Stephen Johnson, President and CEO of OmniComm.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“I am glad that two years of discussions with OmniComm has culminated in the acquisition of OmniComm by Anju. With the financial backing of Abry Partners and the new technology available at Anju, we can realize the potential that both companies have to become the leader in providing software, data and services to the life sciences community,” said Kurien Jacob, Founder and Chairman of Anju Software.
“This merger positions Anju as the fastest-growing provider in the eClinical arena, and the complementary products of the two companies now form a truly comprehensive eClinical suite,” commented Marc Eigner, CEO of Anju.
Stockholders of OmniComm, holding at least a majority of the outstanding shares of voting stock, approved the merger agreement by written consent, and the closing occurred on September 18, 2019. With the completion of the transaction, shares of OmniComm’s common stock have been retired and shareholders have the right to receive $0.41032 per share, without interest, representing a 58% premium to the closing price on July 15, 2019, the day on which the merger was announced.
Crosstree Capital Securities, LLC served as OmniComm’s financial advisor, and Foley & Lardner LLP served as OmniComm’s legal counsel in the transaction. Madison Park Group LLC served as Anju’s financial advisor, and Snell & Wilmer L.L.P. served as Anju’s legal counsel in the transaction.
Date: September 23, 2019
Source: Bakersfield
